From Heparin to Gpiib/Iiia Inhibitors and Doacs: The Revolution in Antithrombotic Therapy
Main Article Content
Abstract
Acute Coronary Syndrome (ACS) remains a significant global burden, necessitating ongoing innovation in therapeutic strategies. Over the past three decades, landmark clinical trials such as PRISM, PRISM-PLUS, PARAGON A, PARAGON B, PURSUIT, and GUSTO IV-ACS have shaped our understanding and management of ACS. These studies provided pivotal data on the role of antithrombotic agents, glycoprotein IIb/IIIa inhibitors, and tailored therapeutic approaches in high-risk populations. This review explores the design, outcomes, and impact of these foundational trials while tracing the evolution of ACS management to current guidelines and practices. Furthermore, we analyze how the insights from these trials have influenced contemporary clinical decision-making and identify the gaps they left for future research. By revisiting these landmark studies, we aim to contextualize their legacy and discuss their relevance in the era of precision medicine and novel therapeutic modalities.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Fuster, V, Badimon, L, Badimon, JJ, Chesebro, JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992;326:242-250
II. 2.Willerson, JT, Golino, P, Eidt, J, Campbell, WB, Buja, M. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989;80:198-205
III. Coller, BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy.
Circulation1995;92:2373-2380
IV. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998 May 21;338(21):1488-97.
doi: 10.1056/NEJM199805213382102. Erratum in: N Engl J Med 1998 Aug 6;339(6):415. PMID: 9599103.
V. Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. Am Heart J. 2002 Feb;143(2):242-8.
doi: 10.1067/mhj.2002.120145. PMID: 11835026.
VI. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. (1998). Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The New England Journal of Medicine, 339(7), 436–443. https://doi.org/10.1056/NEJM199808133390704
VII. Simoons ML; GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet. 2001 Jun16;357(9272):1915-24.doi:10.1016/s0140-6736(00)05060-1.PMID: 11425411.
VIII. Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., Goto, S., Murphy, S. A., Plotnikov, A. N., Schneider, D., Sun, X., Verheugt, F. W. A., Gibson, C. M., & ATLAS ACS 2-TIMI 51 Investigators. (2012). Rivaroxaban in patients with a recent acute coronary syndrome. The New England Journal of Medicine, 366(1), 9–19. https://doi.org/10.1056/NEJMoa1112277
IX. Gibson, C. M., Mehran, R., Bode, C., Halperin, J., Verheugt, F. W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., Korjian, S., Daaboul, Y., Lip, G. Y. H., Cohen, M., Husted, S., Peterson, E. D., & Fox, K. A. (2016). Prevention of bleeding in patients with atrial fibrillation undergoing PCI. The New England Journal of Medicine, 375(25), 2423–2434.
https://doi.org/10.1056/NEJMoa1611594
X. Cannon, C. P., Bhatt, D. L., Oldgren, J., Lip, G. Y. H., Ellis, S. G., Kimura, T., Maeng, M., Merkely, B., Zeymer, U., Gropper, S., Nordaby, M., Kleine, E., Harper, R., Manassie, J., Januzzi, J. L., Ten Berg, J. M., Steg, P. G., Hohnloser, S. H., & RE-DUAL PCI Steering Committee and Investigators. (2017). Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. The New England Journal of Medicine, 377(16), 1513–1524.
https://doi.org/10.1056/NEJMoa1708454
XI. Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., Widimsky, P., Hori, M., Avezum, A., Piegas, L. S., Branch, K. R. H., Probstfield, J., Bhatt, D. L., Zhu, J., Liang, Y., … COMPASS Investigators. (2017). Rivaroxaban with or without aspirin in stable cardiovascular disease. The New England Journal of Medicine, 377(14), 1319–1330.
https://doi.org/10.1056/NEJMoa1709118
XII. Vranckx, P., Valgimigli, M., Eckardt, L., Tijssen, J., Lewalter, T., Gargiulo, G., Batushkin, V., Campo, G., Lysak, Z., Vakaliuk, I., Milewski, K., Laeis, P., Reimitz, P.-E., Smolnik, R., Zierhut, W., & Goette, A. (2019). Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet, 394(10206), 1335–1343. https://doi.org/10.1016/S0140-6736(19)31872-0
XIII. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423-2434.
XIV. Ferguson, J. J., Califf, R. M., Antman, E. M., Cohen, M., Grines, C. L., Goodman, S., Kereiakes, D. J., Langer, A., Mahaffey, K. W., Nessel, C. C., Armstrong, P. W., Avezum, A., Aylward, P., Becker, R. C., Biasucci, L., Borzak, S., Col, J., Frey, M. J., Fry, E., SYNERGY Trial Investigators. (2004). Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial: Primary results of the SYNERGY randomized trial. JAMA: The Journal of the American Medical Association, 292(1), 45–54.
https://doi.org/10.1001/jama.292.1.45
XV. 15.Yusuf, S., Mehta, S. R., Chrolavicius, S., Afzal, R., Pogue, J., Granger, C. B., Budaj, A., Peters, R. J. G., Bassand, J.-P., Wallentin, L., Joyner, C., Fox, K. A. A., & OASIS-6 Trial Group. (2006). Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA: The Journal of the American Medical Association, 295(13), 1519–1530.
https://doi.org/10.1001/jama.295.13.joc60038
XVI. Montalescot, G., White, H. D., Gallo, R., Cohen, M., Steg, P. G., Aylward, P. E. G., Bode, C., Chiariello, M., King, S. B., 3rd, Harrington, R. A., Desmet, W. J., Macaya, C., Steinhubl, S. R., & STEEPLE Investigators. (2006). Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. The New England Journal of Medicine, 355(10), 1006–1017.
https://doi.org/10.1056/NEJMoa052711
XVII. Schulz S, Mehilli J, Neumann FJ, Schuster T, Massberg S, Valina C, Seyfarth M, Pache J, Laugwitz KL, Büttner HJ, Ndrepepa G, Schömig A, Kastrati A; Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 3A Trial Investigators. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J. 2010 Oct;31(20):2482-91. doi: 10.1093/eurheartj/ehq330. Epub 2010 Aug 30. PMID: 20805113.
XVIII. Montalescot, G., Zeymer, U., Silvain, J., Boulanger, B., Cohen, M., Goldstein, P., Ecollan, P., Combes, X., Huber, K., Pollack, C., Jr, Bénezet, J.-F., Stibbe, O., Filippi, E., Teiger, E., Cayla, G., Elhadad, S., Adnet, F., Chouihed, T., Gallula, S., … ATOLL Investigators. (2011). Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet, 378(9792), 693–703. https://doi.org/10.1016/S0140-6736(11)60876-3